TABLE 1.
Baseline characteristics for FFT-CHR, EC and non-randomized NAPLS2 groups
| FFT Group | EC Group | NAPLS2 Group | Test statistic | P value | ||||
|---|---|---|---|---|---|---|---|---|
| n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | χ 2/F (df) | ||
| Age | 50 | 17.86 (4.28) | 44 | 17.83 (3.91) | 401 | 18.78 (4.35) | F(2) = 1.754 | .17 |
| Female, No. (%) | 50 | 18 (36%) | 44 | 19 (43.2%) | 401 | 170 (42.4%) | χ 2(2) = .95 | .68 |
| Baseline antipsychotic use, No. (%) | 50 | 9 (18%) | 44 | 8 (14.1%) | 401 | 67 (16.7%) | χ 2(2) = .95 | .76 |
| Baseline positive symptoms | 50 | 11.84 (3.61) | 44 | 11.23 (3.06) | 401 | 11.67 (3.99) | F(2) = 0.324 | .72 |
| 6-month positive symptoms | 50 | 8.42 (3.90) | 44 | 9.2 (4.58) | 401 | 8.49 (4.53) | F(2) = .532 | .59 |
| Improvement in positive symptoms from baseline to 6 months | 50 | 3.42 (5.37) | 44 | 2.02 (5.10) | 401 | 3.18 (4.22) | F(2) = 1.496 | .22 |
| Predicted risk of conversion | 50 | .18 (.10) | 44 | .16 (.08) | 401 | .17 (.11) | F(2) = .451 | .64 |
| Received psychosocial treatment prior to baseline, No. (%) | 50 | 26 (52%) | 44 | 25 (57%) | 399 | 202 (51%) | χ 2(2) = .62 | .73 |
| Received psychosocial treatment at 6 months, No. (%) | 49 | 37 (75.5%) | 38 | 32 (84%) | 398 | 238 (60%) | χ2(2) = 12.40 | .002 |
Abbreviations: EC, enhanced care; CHR, clinical high-risk; FFT, family-focused therapy; NAPSL2, North American Prodromal Longitudinal Study.